Table 2 Intraoperative details and follow-up results
| Â | No. pts (%) |
|---|---|
Surgical procedures | Â |
 Ureteroureterostomy | 12 (30%) |
  Open | 11 (28%) |
  Robotic | 1 (3%) |
 Ureteroneocystostomy | 22 (55%) |
  Open | 17 (43%) |
  Laparoscopic | 4 (10%) |
  Robotic | 1 (3%) |
 Nephroureterectomy | 5 (13%) |
  Open | 2 (5%) |
  Laparoscopic | 3 (8%) |
 Ureteral stent placement | 1 (3%) |
Concomitant gynecologic operation | 13 (33%) |
 Total hysterectomy + pelvic endometrial nodules resection | 2 (5%) |
 Total hysterectomy + salpingo-oophorectomy | 3 (8%) |
 Salpingo-oophorectomy + pelvic endometrial nodules resection | 2 (5%) |
 Pelvic endometrial nodules resection | 1 (3%) |
 Salpingo-oophorectomy | 3 (8%) |
 Myomectomy | 2 (5%) |
Mean operative time, min (range) | 152.4 (19–380) |
Mean post-operative hospitalization, day (range) | 6.7 (2–13) |
Surgical complications, n | 3 (8%) |
 Sigmoid colon injury/intestinal obstruction/blood transfusion | 1/1/1 |
Postoperative endocrine therapy, n | 9 (23%) |
Total follow-up patients, n | 28 (70%) |
 Ureteroureterostomy | 7 |
  Open | 6 |
  Robotic | 1 |
 Ureteroneocystostomy | 16 |
  Open | 13 |
  Laparoscopic | 3 |
 Nephroureterectomy | 4 |
  Open | 1 |
  Laparoscopic | 3 |
 Ureteral stent placement | 1 |
Median follow-up time, month (range) | 71 (11–150) |
Positive follow-up results, n | 3 |
 Flank pain (open ureteroureterostomy group) | 1 |
 Recurrent urinary tract infection (open ureteroneocystostomy group) | 1 |
 Unresolved hydronephrosis (open ureteroureterostomy group) | 1 |